Skip to main content

Insulin glargine

26-05-2022 | Insulin glargine | News

Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

The addition of insulin glargine 300 units/mL to glucagon-like peptide-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.

09-11-2021 | Travel | News

Insulin degludec could simplify travel across times zones

Insulin degludec offers similar glycemic outcomes to insulin glargine U100, along with more straightforward dosing, for people with insulin-treated diabetes crossing time zones, a small study suggests.

19-10-2021 | Tirzepatide | News

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

04-10-2021 | EASD 2021 | Conference coverage | News

Real-world data show comparable benefits for second-generation insulins in type 2 diabetes

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.

02-08-2021 | Insulin glargine | News

First interchangeable biosimilar insulin approved in the USA

Click through for more information on this FDA approval

29-06-2021 | ADA 2021 | Conference coverage | News

​​​​​​​Trial GRADEs effectiveness of four common second-line type 2 diabetes drugs

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

27-06-2021 | ADA 2021 | Conference coverage | News

Further support for insulin degludec to reduce nocturnal hypoglycemia risk in type 1 diabetes

Use of insulin degludec is associated with a reduced risk for recurrent nocturnal hypoglycemia as measured by hourly plasma glucose among adults with type 1 diabetes, suggest findings from the overnight substudy of the HypoDeg trial.

27-06-2021 | ADA 2021 | Conference coverage | News

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.